HM Payson & Co. Sells 918 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

HM Payson & Co. lessened its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 33,748 shares of the company’s stock after selling 918 shares during the quarter. HM Payson & Co.’s holdings in GE HealthCare Technologies were worth $2,638,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of GEHC. Capital Performance Advisors LLP bought a new stake in GE HealthCare Technologies during the third quarter worth about $26,000. Ashton Thomas Securities LLC bought a new stake in GE HealthCare Technologies during the third quarter worth about $26,000. Darwin Wealth Management LLC bought a new stake in GE HealthCare Technologies during the third quarter worth about $31,000. Continuum Advisory LLC lifted its position in GE HealthCare Technologies by 101.8% during the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after purchasing an additional 168 shares during the period. Finally, Bank of Jackson Hole Trust bought a new stake in GE HealthCare Technologies during the fourth quarter worth about $32,000. Institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Stock Performance

GE HealthCare Technologies stock opened at $86.58 on Friday. The business has a 50 day moving average of $86.77 and a 200-day moving average of $86.15. GE HealthCare Technologies Inc. has a 1 year low of $74.51 and a 1 year high of $94.80. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. The company has a market capitalization of $39.59 billion, a P/E ratio of 20.00, a P/E/G ratio of 3.19 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The company had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.33 billion. On average, equities research analysts predict that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GEHC has been the subject of several recent analyst reports. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and upped their price objective for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. Citigroup boosted their target price on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Finally, Wells Fargo & Company boosted their target price on GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $97.67.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.